Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical Co. (TAK) reports that the U.S. FDA has accepted, under Priority Review, its New Drug Application for zasocitinib (TAK-279), an investigational oral TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis. The Prescription Drug User Fee Act target action date is in the first quarter of 2027.
The application is backed by global Phase 3 LATITUDE PsO 3001 and 3002 studies, which met all primary and ranked secondary endpoints and showed about 70% of patients achieved clear or almost clear skin at week 16, with a safety profile consistent with earlier studies. A Phase 3 open-label study (LATITUDE PsO 3003) in roughly 2,100 participants supports long‑term safety and efficacy, and a marketing authorization application has also been accepted by the EMA. Takeda states this NDA filing has no significant impact on its full-year consolidated financial forecast for the fiscal year ending March 31, 2027.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a notice of proposed sale under Rule 144 for American Depositary Shares by Chief Transformation Officer Lauren Rusckowski Duprey. The notice covers 34,535 ADSs, which were acquired through vested Restricted Stock Unit Awards on July 30, 2024.
The broker listed is Interactive Brokers LLC, with the ADSs indicated for trading on the NYSE. The notice also reports that over the past three months, 47,586 ADSs were sold on July 13, 2026 for $813,720.60, with the remark that this earlier sale was made to satisfy tax obligations related to share vesting effective that date.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported that Andrew Stewart Plump, its President of R&D and a director, sold 116,191 American Depositary Shares on September 2, 2026 at $18.49 per share through a trust. The trust held 145,465 ADS after the sale, and he also reported 766,569 ADS held directly. The sale was made under a Rule 10b5-1 trading plan adopted on May 15, 2026.
TAKEDA PHARMACEUTICAL CO LTD (TAK) received a notice that officer Andrew Stewart Plump, through the ANDREW S PLUMP 2020 REV TR U/A 12/2/20 and Fidelity Brokerage Services LLC as attorney-in-fact, intends under Rule 144 to sell up to 116,191 shares of Takeda common stock on the NYSE.
The notice also reports that during the prior three months, Plump sold 19,651 shares of Takeda common stock on August 19, 2026 for $363,348.49.
Takeda Pharmaceutical Company Limited (TAK) reports that the U.S. FDA has approved MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera, a chronic blood cancer. MIMRYLO is a first-in-class subcutaneous hepcidin mimetic designed to regulate iron distribution and reduce excess red blood cell production to maintain hematocrit control, the primary treatment goal in PV.
The approval is based on the global Phase 3 VERIFY study in 293 patients, where 76.9% of patients achieved clinical response during Weeks 20–32 and the drug met all efficacy endpoints, including hematocrit control, reduced phlebotomy need and improved fatigue, with a generally favorable safety profile. Common adverse reactions included injection site reactions (56%) and anemia (16%). The company states that this U.S. approval does not change its consolidated financial forecast for the fiscal year ending March 31, 2027, and highlights MIMRYLO as part of three new medicines expected to support future growth.
TAKEDA PHARMACEUTICAL CO LTD (TAK) director and officer Andrew Stewart Plump, President, R&D, reported the sale of 19,651 American Depositary Shares of Takeda on August 19, 2026 at $18.49 per ADS. The shares were held indirectly by a trust, which held 261,656 ADS afterward. Separately, Plump reported 766,569 ADS held directly following the reported transactions. The sale was effected under a Rule 10b5-1 trading plan adopted on May 15, 2026.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported an insider share sale by Chief Human Resources Officer Nicola Deidre Petal Greenway. On 2026-08-18, she sold 12,980 American Depositary Shares at $18.1139 per share in an open market or private transaction, and 40,049 ADS remain held directly.
TAKEDA PHARMACEUTICAL CO LTD (TAK) received a Rule 144 notice covering a planned sale of common stock beneficially owned for the account of officer Andrew Stewart Plump. The filing indicates plans to sell 19,651 shares of TAK common stock through Fidelity Brokerage Services LLC on or about August 19, 2026 on the NYSE.
The shares to be sold were acquired from the issuer on August 20, 2020 as RSU's and PSU's and are held in the ANDREW S PLUMP 2020 REV TR U/A 12/2/20. The filing lists an aggregate market value of $363,348.49 for the proposed sale and shows 1,579,836,830 shares outstanding of TAK common stock as context.
Nicola Greenway filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited through Interactive Brokers LLC on August 14, 2026 on the NYSE. The ADSs derive from Restricted Stock Unit Awards – Vested as of July 31, 2026.
The filing also lists prior sales over the past three months, including 6,774 ADSs for $115,835.40 and 34,603 ADSs for $605,552.50, both dated August 10, 2026.
Takeda Pharmaceutical Co. Ltd. reports that Chief Medical Officer Farajallah Awny Samaan Botros sold 14,006 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction represents a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, Botros directly holds 116,177 American Depositary Shares.